<DOC>
	<DOCNO>NCT02043912</DOCNO>
	<brief_summary>In epidemiological point prevalence study , medication profile patient haloperidol treatment check drug interaction risk QT-prolongation . Additional clinical risk factor develop QT-prolongation safety measurement document .</brief_summary>
	<brief_title>Drug Interactions With Risk QT-prolongation General Hospital</brief_title>
	<detailed_description>Study design : epidemiological point prevalence study Target population : Patients haloperidol treatment The following aspect investigate : - The medication profile check drug interaction risk QT-prolongation . - Clinical risk factor develop QT-prolongation ( gender , age , ( history ) cardiovascular disease , comorbidity , ... ) lab result collect . - Safety measurement ( e.g . ECG ) document .</detailed_description>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>treatment haloperidol ( started hospital ) age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>QT-prolongation</keyword>
	<keyword>Torsade de Pointes</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Drug interaction</keyword>
</DOC>